Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 2, 2011, Pages 256-264

  Perez Alvarez, Roberto ^a   Perez de Lis, Marta ^a   Diaz Lagares, Candido ^b   Pego Reigosa, Jose M ^a   Retamozo, Soledad ^b   Bove, Albert ^b   Brito Zeron, Pilar ^b   Bosch, Xavier ^b   Ramos Casals, Manuel ^b  

^a HOSPITAL DO MEIXOEIRO   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Adalimumab; Anti TNF; Etanercept; Infliximab; Interstitial lung disease

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CEFTRIAXONE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; ISONIAZID; METHOTREXATE; METHYLPREDNISOLONE; OSELTAMIVIR; PYRAZINAMIDE; RIFAMPICIN; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BACTERIUM CULTURE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FEVER; FIBROSING ALVEOLITIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; LUNG BIOPSY; LUNG INFILTRATE; LUNG TUBERCULOSIS; MALAISE; MORTALITY; ONSET AGE; ORGANIZING PNEUMONIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SURVIVOR; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051801842     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.11.002     Document Type: Article

References (69)

1. Camus P., Fanton A., Bonniaud P., Camus C., Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004, 71(4):301-326.
2. Ramos-Casals M., Brito-Zerón P., Muñoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86(4):242-251.
3. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000, 43(11):2383-2390.
4. Favalli E.G., Sinigaglia L., Varenna M., Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002, 11(11):753-755.
5. Ramos-Casals M., Brito-Zerón P., Cuadrado M.J., Khamashta M.A. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep 2008, 10(6):442-448.
6. Ramos-Casals M., Brito-Zerón P., Soto M.J., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008, 22(5):847-861.
7. Ramos-Casals M., Roberto-Perez-Alvarez, Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9(3):188-193. BIOGEAS Study Group.
8. Ramos-Casals M., Brito-Zerón P., Muñoz S., Soto M.J. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008, 87(6):345-364. BIOGEAS STUDY Group.
9. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002, 165(2):277-304. American Thoracic Society; European Respiratory Society.
10. Kishi J., Nanki T., Watanabe K., Takamura A., Miyasaka N. A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology (Oxford) 2009, 48(4):447-448.
11. Nouijai A., Mounach A., Ghozlani I., Achemlal L., Bezza A., El Maghraoui A. Fibrosing alveolitis after treatement of rheumatoid arthritis by infliximab. Presse Med 2009, 38(10):e17-e20.
12. Taki H., Kawagishi Y., Shinoda K., Hounoki H., Ogawa R., Sugiyama E., et al. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int 2009 Apr 17, [Epub ahead of print].
13. Díez Piña J.M., Vázquez Gómez O., Mayoralas Alises S., García Jiménez J.D., Alvaro Alvarez D., Rodríguez Bolado M.P. Etanercept as a possible trigger of fatal pulmonary fibrosis. Arch Bronconeumol 2008, 44(7):393-395.
14. Dubosc A.E., Perroud A.M., Bagot M., Farenq V., Chevalier X., Maitre B., et al. Cutaneous granulomas during infliximab therapy for spondyloarthropathy. J Rheumatol 2008, 35(6):1222-1223.
15. El-Hag K., Dercken H.G., Prenzel R., Hölzle E. Drug-induced alveolitis associated with infliximab/azathioprine therapy. Pneumologie 2008, 62(4):204-208.
16. Heresi G.A., Farver C.F., Stoller J.K. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008, 76(4):449-453.
17. Soubrier M., Jeannin G., Kemeny J.L., Tournadre A., Caillot N., Caillaud D., et al. Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 2008, 75(3):362-365.
18. Veerappan S.G., O'Morain C.A. Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis. Eur J Gastroenterol Hepatol 2009, 21(7):830-832.
19. Wiener C.M., Muse V.V., Mark E.J. Case records of the Massachusetts General Hospital. Case 33-2008. A 63-year-old woman with dyspnea on exertion. N Engl J Med 2008, 359(17):1823-1832.
20. Hagiwara K., Sato T., Takagi-Kobayashi S., Hasegawa S., Shigihara N., Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 2007, 34(5):1151-1154.
21. Huggett M.T., Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford) 2006, 45(10):1312-1313.
22. Lindsay K., Melsom R., Jacob B.K., Mestry N. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford) 2006, 45(8):1048-1049.
23. Mori S., Imamura F., Kiyofuji C., Sugimoto M. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatol 2006, 16(4):251-255.
24. Tournadre A., Ledoux-Eberst J., Poujol D., Dubost J.J., Ristori J.M., Soubrier M. Exacerbation of interstitial lung disease during etanercept therapy: two cases. Joint Bone Spine 2008, 75(2):215-218.
25. Allanore Y., Devos-François G., Caramella C., Boumier P., Jounieaux V., Kahan A. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006, 65(6):834-835.
26. Hennum J., Nace J., Shammash E., Gertner E. Infliximab-associated pneumonitis in rheumatoid arthritis. Rheumatology 2006, 33(9):1917-1918.
27. Kang M.J., Lee Y.H., Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci 2006, 21(5):946-949.
28. Ostör A.J., Chilvers E.R., Somerville M.F., Lim A.Y., Lane S.E., Crisp A.J., et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006, 33(3):622-628.
29. Pataka A., Tzouvelekis A., Bouros D. Infliximab-induced non-specific interstitial pneumonia and lupus-like eruption. Eur J Intern Med 2006, 17(7):520.
30. Quintos-Macasa A.M., Quinet R. Enbrel-induced interstitial lung disease. South Med J 2006, 99(7):783-784.
31. Schoe A., van der Laan-Baalbergen N.E., Huizinga T.W., Breedveld F.C., van Laar J.M. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum 2006, 55(1):157-159.
32. Villeneuve E., St-Pierre A., Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006, 33(6):1189-1193.
33. Weatherhead M., Masson S., Bourke S.J., Gunn M.C., Burns G.P. Interstitial pneumonitis after infliximab therapy for Crohn's disease. Inflamm Bowel Dis 2006, 12(5):427-428.
34. Tengstrand B., Ernestam S., Engvall I.L., Rydvald Y., Hafström I. TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports. Lakartidningen 2005, 102(49):3788-3790. 3793.
35. Yousem S.A., Dacic S. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. Mod Pathol 2005, 8(5):651-655.
36. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol 2004, 33(4):276-277.
37. Leon R.J., Gonsalvo A., Salas R., Hidalgo N.C. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004, 79(7):949. 953.
38. Martín Carrasco C., Hortal Reina B., Fernández Vázquez E. Pulmonary infiltrates after initiation of treatment with infliximab for adult Still's disease. Arch Bronconeumol 2005, 41(6):355.
39. Panagi S., Palka W., Korelitz B.I., Taskin M., Lessnau K.D. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease. Inflamm Bowel Dis 2004, 10(3):274-277.
40. Swords R., Power D., Fay M., O'Donnell R., Murphy P.T. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004, 77(1):103-104.
41. Courtney P.A., Alderdice J., Whitehead E.M. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2003, 49(4):617.
42. Kramer N., Chuzhin Y., Kaufman L.D., Ritter J.M., Rosenstein E.D. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2002, 47(6):670-671.
43. Kramer N., Chuzhin Y., Kaufman L.D., Ritter J.M., Rosenstein E.D. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2003, 49(4):617.
44. Peno-Green L., Lluberas G., Kingsley T., Brantley S. Lung injury linked to etanercept therapy. Chest 2002, 122(5):1858-1860.
45. Koike T., Harigai M., Inokuma S., Inoue K., Ishiguro N., Ryu J., et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009, 36(5):898-906.
46. Takeuchi T., Tatsuki Y., Nogami Y., Ishiguro N., Tanaka Y., Yamanaka H., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67(2):189-194.
47. Wolfe F., Caplan L., Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007, 36(3):172-178.
48. De Bandt M., Sibilia J., Le Loet X., Prouzeau S., Fautrel B., Marcelli C., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005, 7(3):R545-R551.
49. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P. British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54(8):2368-2376.
50. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M. BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010, 69(6):1086-1091.
51. Piguet P.F., Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994, 7(3):515-518.
52. Miyazaki Y., Araki K., Vesin C., Garcia I., Kapanci Y., Whitsett J.A., et al. Expression of a tumour necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis: a mouse model of progressive pulmonary fibrosis. J Clin Invest 1995, 96(1):250-259.
53. Alho H.S., Maasilta P.K., Harjula A.L., Hämmäinen P., Salminen J., Salminen U.S. Tumor necrosis factor-a in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2003, 76(3):516-523.
54. Kuroki M., Noguchi Y., Shimono M., Tomono K., Tashiro T., Obata Y., et al. Repression of bleomycin-induced pneumopathy by TNF. J Immunol 2003, 170(1):567-574.
55. Elias J.A. Tumor necrosis factor interacts with interleukin-1 and interferon to inhibit fibroblast proliferation via fibroblast prostaglandin-dependent and independent mechanisms. Am Rev Respir Dis 1988, 38(6):652-658.
56. Sullivan D.E., Ferris M., Nguyen H., Abboud E., Brody A.R. TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J Cell Mol Med 2009, 13(8B):1866-1876.
57. Yamasaki M., Kang H.R., Homer R.J., Chapoval S.P., Cho S.J., Lee B.J., et al. P21 regulates TGF-beta1-induced pulmonary responses via a TNF-alpha-signaling pathway. Am J Respir Cell Mol Biol 2008, 38(3):346-353.
58. Wynn T.A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004, 4(8):583-594.
59. Burton C., Kaczmarski R., Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003, 348(26):2690-2691.
60. Alexandrescu D.T., Dutcher J.P., O'Boyle K., Albulak M., Oiseth S., Wiernik P.H. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004, 45(11):2321-2325.
61. Hiraga J., Kondoh Y., Taniguchi H., Kinoshita T., Naoe T. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005, 81(2):169-170.
62. Macartney C., Burke E., Elborn S., Magee N., Noone P., Gleadhill I., et al. Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim. Leuk Lymphoma 2005, 46(10):1523-1526.
63. Wagner S.A., Mehta A.C., Laber D.A. Rituximab-induced interstitial lung disease. Am J Hematol 2007, 82(10):916-919.
64. Kim K.M., Kim H.C., Jeon K.N., Kim H.G., Kang J.H., Hahm J.R., et al. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J 2008, 49(1):155-158.
65. Liu X., Hong X.N., Gu Y.J., Wang B.Y., Luo Z.G., Cao J. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 2008, 49(9):1778-1783.
66. Bienvenu J., Chvetzoff R., Salles G., Balter C., Tilly H., Herbrecht R., et al. Tumor necrosis factor α release is a major biological event associated with rituximab treatment. Hematol J 2001, 2(6):378-384.
67. Lioté H., Lioté F., Séroussi B., Mayaud C., Cadranel J. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2010, 35(3):681-687.
68. Attili A.K., Kazerooni E.A., Gross B.H., Flaherty K.R., Myers J.L., Martinez F.J. Smoking-related interstitial lung disease: radiologic-clinical-pathologic correlation. Radiographics 2008, 28(5):1383-1396.
69. Ramos-Casals M., Tzioufas A.G., Font J. Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005, 64(3):347-354.